Article

Antidepressant Use During Breastfeeding.

Department of Psychiatry, Haukeland University Hospital, P.O. Box 23 Sandviken, N-5812 Bergen, Norway.
Current Women s Health Reviews 02/2011; 7(1):28-34. DOI: 10.2174/157340411794474784
Source: PubMed

ABSTRACT BACKGROUND: The treatment of breastfeeding mothers with depression raises several dilemmas, including the possible risk of drug exposure through breast milk for the infant. This article provides background information and presents practical advice and recommendations for the clinician dealing with the treatment of depression and related disorders in the postpartum period. METHODS: An electronic search for relevant articles was performed. As the use of tricyclic antidepressants has considerably decreased during the last decade and no new information on breastfeeding has emerged for the tricyclics in this period, this review exclusively focuses on the newer, non-tricyclic compounds. RESULTS: Most newer antidepressants produce very low or undetectable plasma concentrations in nursing infants. The highest infant plasma levels have been reported for fluoxetine, citalopram and venlafaxine. Suspected adverse effects have been reported in a few infants, particularly for fluoxetine and citalopram. CONCLUSIONS: Infant exposure of antidepressants through breast milk is generally low to very low. We consider that when antidepressant treatment is indicated in women with postpartum depression, they should not be advised to discontinue breastfeeding. Paroxetine and sertraline are most likely suitable first-line agents. Although some concern has been expressed for fluoxetine, citalopram and venlafaxine, we nevertheless consider that if the mother has been treated with one of these drugs during pregnancy, breast-feeding could also be allowed during continued treatment with these drugs in the postpartum period. However, an individual risk-benefit assessment should always be performed.

0 Bookmarks
 · 
103 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: ZUSAMMENFASSUNG Hintergrund: Der vorliegende Artikel gibt eine Übersicht über die aktuelle Studienlage zu Prävalenz, Risikofaktoren und Behandlung peripartaler Depression. Methode: Relevante Literatur wurde auf Medline sowie in der Cochrane Library unter "peri/pre/post", "partum/par-tal/natal", "maternal/motherhood/pregnancy" und "de-pression/affective disorder" identifiziert. Ergebnisse: Mit einer Prävalenz von 18,4 % in der Schwangerschaft und 19,2 % in der frühen Mutterschaft sind Depressionen die häufigsten Erkrankungen in der Pe-ripartalzeit. Bereits präpartal sind sie assoziiert mit erhöh-tem Frühgeburtsrisiko, geringerem Geburtsgewicht oder veränderter fötaler Herzaktivität. Langfristig werden bei den Kindern beeinträchtigte kognitive oder emotionale Fä-higkeiten beobachtet. Als Risikofaktoren gelten depressive Vorerkrankung, mangelnde partnerschaftliche wie soziale Unterstützung und belastende Lebensereignisse. Eine pe-ripartale Depression kann psychotherapeutisch wie psy-chopharmakologisch effektiv behandelt werden. Die der-zeitige Datengrundlage ermöglicht den Einsatz ausge-wählter antidepressiver Substanzen in Schwangerschaft wie Stillzeit. Niederschwellige psychosoziale Hilfen bieten vielerorts auch die Schwangerenberatungsstellen. Aller-dings werden wohl nicht mehr als 20 % der betroffenen Frauen erkannt, obwohl mit der Edinburgh Postnatal De-pression Scale (EPDS) und den beiden Whooley-Fragen ein schnelles Screening möglich ist.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Mental disorders are among the most common morbidities of pregnancy and the postnatal period, and can have adverse effects on the mother, her child, and family. This Series paper summarises the evidence about epidemiology, risk factors, identification, and interventions for non-psychotic mental disorders. Although the phenomenology and risk factors for perinatal mental disorders are largely similar to those for the disorders at other times, treatment considerations differ during pregnancy and breastfeeding. Most randomised controlled trials have examined psychosocial and psychological interventions for postnatal depression, with evidence for effectiveness in treating and preventing the disorder. Few high-quality studies exist on the effectiveness or safety of pharmacological treatments in the perinatal period, despite quite high prescription rates. General principles of prescribing of drugs in the perinatal period are provided, but individual risk-benefit analyses are needed for decisions about treatment. Copyright © 2014 Elsevier Ltd. All rights reserved.
    The Lancet 11/2014; 384(9956):1775-88. · 39.21 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Context-awareness is a central aspect in the design of ubiquitous systems, characterizing their ability to observe the environment's context changes and adapt its structure and behavior according. Since those systems can be able to make autonomous decisions (i.e., without direct user intervention), dependability becomes an important requirement. The exception handling is a well-known error recovery technique employed to improve the software robustness and contributes to the overall software system's reliability and dependability. However, despite its benefits, exception handling still not widely used in the development of ubiquitous systems. In fact, we argue that is consequence of the lack of a proper exception handling mechanism to support it during the development and execution phases. In order to address this problem, we propose a context-aware exception handling mechanism designed specifically for context-aware ubiquitous systems. The proposed mechanism is implemented as a Java-based framework that provides a task-based model for building robust ubiquitous systems. A prototype of a ubiquitous parking control system is implemented to explore and validate the features of the proposed mechanism.
    2014 28th International Conference on Advanced Information Networking and Applications Workshops (WAINA); 05/2014

Full-text (2 Sources)

Download
9 Downloads
Available from
Jun 10, 2014